December 21, 2020 Oral XPOVIO® Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO® Addressable Patient Population - Oral XPOVIO® is Now the Only Approved Multiple Myeloma Drug Indicated as Part of a Once-Weekly Bortezomib Combination Regimen - First Multiple Myeloma Drug with a New Mechanism of Action Approved by the FDA in the Second-Line Setting Since 2016 - FDA Approval Comes Approximately Three Months Ahead of Target PDUFA Date -
SHANGHAI and HONG KONG, Dec. 21, 2020 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc. (Nasdaq: KPTI) for oral XPOVIO
(2)
DJ EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
EQS-News / 21/12/2020 / 15:21 UTC+8 Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy Oral XPOVIO(R) Approval as Combination Therapy in Patients with Multiple
Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO(R) Addressable Patient Population - Oral XPOVIO(R) is Now the Only Approved Multiple Myeloma Drug Indicated
TodayIR: Antengene Announces its U S Partner, -2- finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Monday, 21 December 2020, 10:09 am | Pacific Edge Peer reviewed publication of further independent, real-world clinical evidence highlights
the effectiveness, safety and long term clinical utility from inclusion of Cxbladder
in a new standard of care in mainstream clinical use. Cancer diagnostics company, . More
Thursday, 19 November 2020, 10:15 am | Pacific Edge New Zealand cancer diagnostics company Pacific Edge Limited (NZX: PEB) today announces
a new leadership structure to strengthen the executive team of its US based subsidiary,
Pacific Edge Diagnostics USA Limited (PEDUSA). Coupled with this Pacific Edge is . More
Wednesday, 25 March 2020, 11:21 am | Pacific Edge Cancer diagnostic company, Pacific Edge, advises that its medical and diagnostic
This article originally appeared on Undark.
When chatting at cocktail parties about his job, Mark Ratain, an oncologist and pharmacologist at the University of Chicago, often asks a short riddle: Your doctor gives you a prescription for a new drug. The pharmacist says, Make sure you take it on an empty stomach, twice a day. What do you think would happen if you took it with food?
Most don t get the answer right. Nobody would ever say, Well, I could die from an overdose, Ratain says.
Advertisement:
That s exactly what could happen to anyone taking the drug nilotinib approved by the U.S. Food and Drug Administration in 2007 to treat the blood cancer chronic myelogenous leukemia. The drug is among the most effective cancer therapies; a patient taking it may have a 96 percent chance of surviving the cancer for at least six years, according to one of the most recent long-term studies. But the FDA-approved label for nilotinib carries a black box warning: Take it on an empty s